AI assistant
Biohit Oyj — Director's Dealing 2022
Jan 18, 2022
3304_rns_2022-01-18_367c2b65-47e4-495e-94f8-6ece1d7c8b3e.pdf
Director's Dealing
Open in viewerOpens in your device viewer
BIOHIT HealthCare
Innovating for Health
Biohit Oyj - Managers' Transactions - Mäki
Person subject to the notification requirement
Name: Minna Mäki
Position: Other senior manager
Issuer: Biohit Oyj
LEI: 74370089ATTSNBXJVT29
Notification type: INITIAL NOTIFICATION
Reference number: 9334/4/6
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021A
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 8000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021B
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 8000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021C
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 8000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021D
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 8000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021E
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 8000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 8000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021A
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 10000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021B
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 10000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021C
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 10000 Volume weighted average price: 0 EUR
Transaction date: 2022-01-16
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021D
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 10000 Volume weighted average price: 0 EUR
CEO Päivi Siltala, Biohit Oyj
tel. +358 9 773 861
www.biohithealthcare.com
Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com